Literature DB >> 34889852

Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Society.

Huamin Wang1, Runjan Chetty2, Mojgan Hosseini3, Daniela S Allende4, Irene Esposito5, Yoko Matsuda6, Vikram Deshpande7, Jiaqi Shi8, Deepti Dhall9, Kee-Taek Jang10, Grace E Kim11, Claudio Luchini12, Rondell P Graham13, Michelle D Reid14, Olca Basturk15, Ralph H Hruban16, Alyssa Krasinskas14, David S Klimstra15, Volkan Adsay17.   

Abstract

Currently, there are no internationally accepted consensus guidelines for pathologic evaluation of posttherapy pancreatectomy specimens. The Neoadjuvant Therapy Working Group of Pancreatobiliary Pathology Society was formed in 2018 to review grossing protocols, literature, and major issues and to develop recommendations for pathologic evaluation of posttherapy pancreatectomy specimens. The working group generated the following recommendations: (1) Systematic and standardized grossing and sampling protocols should be adopted for pancreatectomy specimens for treated pancreatic ductal adenocarcinoma (PDAC). (2) Consecutive mapping sections along the largest gross tumor dimension are recommended to validate tumor size by histology as required by the College of American Pathologists (CAP) cancer protocol. (3) Tumor size of treated PDACs should be measured microscopically as the largest dimension of tumor outer limits that is bound by viable tumor cells, including intervening stroma. (4) The MD Anderson grading system for tumor response has a better correlation with prognosis and better interobserver concordance among pathologists than does the CAP system. (5) A case should not be classified as a complete response unless the entire pancreas, peripancreatic tissues, ampulla of Vater, common bile duct, and duodenum adjacent to the pancreas are submitted for microscopic examination. (6) Future studies on tumor response of lymph node metastases, molecular and/or immunohistochemical markers, as well as application of artificial intelligence in grading tumor response of treated PDAC are needed. In summary, systematic, standardized pathologic evaluation, accurate tumor size measurement, and reproducible tumor response grading to neoadjuvant therapy are needed for optimal patient care. The criteria and discussions provided here may provide guidance towards these goals.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34889852      PMCID: PMC9106848          DOI: 10.1097/PAS.0000000000001853

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  39 in total

1.  Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.

Authors:  Linda M Youngwirth; Daniel P Nussbaum; Samantha Thomas; Mohamed A Adam; Dan G Blazer; Sanziana A Roman; Julie A Sosa
Journal:  J Surg Oncol       Date:  2017-04-13       Impact factor: 3.454

2.  Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Authors:  Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang
Journal:  Cancer       Date:  2011-07-06       Impact factor: 6.860

3.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

4.  Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.

Authors:  Jiansheng Wang; Jeannelyn S Estrella; Lan Peng; Asif Rashid; Gauri R Varadhachary; Hua Wang; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Matthew H Katz; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

5.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.

Authors:  John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler
Journal:  Lancet       Date:  2017-01-25       Impact factor: 79.321

6.  Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

Authors:  Edwin R Fisher; Jiping Wang; John Bryant; Bernard Fisher; Eletherios Mamounas; Norman Wolmark
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

7.  Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy.

Authors:  Boris V Janssen; Faik Tutucu; Stijn van Roessel; Volkan Adsay; Olca Basturk; Fiona Campbell; Claudio Doglioni; Irene Esposito; Roger Feakins; Noriyoshi Fukushima; Anthony J Gill; Ralph H Hruban; Jeffrey Kaplan; Bas Groot Koerkamp; Seung-Mo Hong; Alyssa Krasinskas; Claudio Luchini; Johan Offerhaus; Arantza Fariña Sarasqueta; Chanjuan Shi; Aatur Singhi; Thomas F Stoop; Eline C Soer; Elizabeth Thompson; Geertjan van Tienhoven; Marie-Louise F Velthuysen; Johanna W Wilmink; Marc G Besselink; Lodewijk A A Brosens; Huamin Wang; Caroline S Verbeke; Joanne Verheij
Journal:  Mod Pathol       Date:  2020-10-12       Impact factor: 7.842

8.  Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Authors:  Deyali Chatterjee; Matthew H Katz; Wai Chin Foo; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.298

9.  Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cross-specialty Survey From the Pancreatobiliary Pathology Society Grossing Working Group.

Authors:  Deepti Dhall; Jiaqi Shi; Daniela S Allende; Kee-Taek Jang; Olca Basturk; Volkan Adsay; Grace E Kim
Journal:  Am J Surg Pathol       Date:  2021-10-01       Impact factor: 6.298

10.  Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.

Authors:  J P Neoptolemos; D D Stocken; C Tudur Smith; C Bassi; P Ghaneh; E Owen; M Moore; R Padbury; R Doi; D Smith; M W Büchler
Journal:  Br J Cancer       Date:  2009-01-06       Impact factor: 7.640

View more
  3 in total

Review 1.  Critical issues in pathologic evaluation of pancreatic ductal adenocarcinoma resected after neoadjuvant treatment: a narrative review.

Authors:  Mehran Taherian; Huamin Wang
Journal:  Chin Clin Oncol       Date:  2022-06-16

2.  Tumour Size and T-Stage in Pancreatic Cancer Resection Specimens Depend on the Pathology Examination Approach.

Authors:  My Linh Tran; Maia Blomhoff Holm; Caroline Sophie Verbeke
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

3.  The prognostic relevance of examined lymph nodes for accurate staging of resected pancreatic adenocarcinoma.

Authors:  Claudia Zaharia; Marcus Roalsø; Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.